Skip to main content
. 2022 Oct 10;44(4):801–810. doi: 10.1038/s41401-022-00993-5

Fig. 3. AZD4547 blocks necroptosis independent of FGFR or TNF-induced NF-κB activation.

Fig. 3

a TOV21G cells were pretreated with infigratinib (left panel) or erdafitinib (right panel) at the indicated concentrations followed by stimulation with TSZ for 24 h. Cell viability was analyzed by CellTiter‐Glo assay. b HT29 cells were pretreated with AZD4547 (1 μM) for 30 min followed by stimulation with TNFα (200 ng/mL) at the indicated time points. c 293 T cells were transfected with a firefly luciferase reporter to construct a promoter sequence containing NF-κB binding sites. After 24 h, cells were treated indicated for 4 h. d HT29 cells were pretreated with DMSO or AZD4547 and then stimulated with TNFα (20 ng/mL) plus Smac mimetic BV6 (2 μM; TS) for 24 h (left). HT29 cells were pretreated with DMSO or AZD4547 and then stimulated with TNFα (20 ng/mL) plus cycloheximide (5 μg/mL; TC) for 24 h (right). Cell viability was analyzed by CellTiter‐Glo assay. *P < 0.05, **P < 0.01, ***P < 0.001.